-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40

Benzinga·09/08/2026 16:52:30
语音播报
Truist Securities analyst Supawat Thongthip reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $35 to $40.